In clinical practice, these four biomarker profiles/subtypes have been synonymous with the molecular breast cancer subtypes defined by distinct transcriptomic profiles.1 Treatment recommendations are heavily dependent on the expression status of HR and HER2 biomarkers in the initial breast cancer diagnosis. Here, ERBB2 is linked to breast cancer.